Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01614821 · OUTCOME

Overall Response Rate

Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia · Source last updated 2020-01-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
4 years

What was measured

To assess the overall response rate (\>25% reduction in serum IgM from baseline).

Groups in this outcome

Treatment Arm

PCI-32765; ibrutinib PCI-32765: Taken orally, once daily in the morning

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment Arm63

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment Arm57Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        57
denoms
  1. counts
    1. group Id
      OG000
      value
      63
    units
    Participants
description
To assess the overall response rate (\>25% reduction in serum IgM from baseline).
groups
  1. description
    PCI-32765; ibrutinib PCI-32765: Taken orally, once daily in the morning
    id
    OG000
    title
    Treatment Arm
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
4 years
title
Overall Response Rate
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice